Strategies to overcome HIV drug resistance-current and future perspectives
A Temereanca, S Ruta - Frontiers in Microbiology, 2023 - frontiersin.org
The availability of combined antiretroviral therapy (cART) has revolutionized the course of
HIV infection, suppressing HIV viremia, restoring the immune system, and improving the …
HIV infection, suppressing HIV viremia, restoring the immune system, and improving the …
Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir
M Heidary, S Shariati, S Nourigheimasi… - BMC Infectious …, 2024 - Springer
Abstract The Food and Drug Administration (FDA) has licensed many antiretroviral
medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment …
medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment …
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
T Clemente, L Galli, R Lolatto, R Gagliardini, F Lagi… - BMJ open, 2024 - bmjopen.bmj.com
Purpose The PRESTIGIO Registry was established in 2017 to collect clinical, virological and
immunological monitoring data from people living with HIV (PLWH) with documented four …
immunological monitoring data from people living with HIV (PLWH) with documented four …
HIV-1 subtype C drug resistance mutations in heavily treated patients failing integrase strand transfer inhibitor-based regimens in Botswana
KK Seatla, D Maruapula, WT Choga, T Ntsipe… - Viruses, 2021 - mdpi.com
There are limited real-world mutational and virological outcomes data of treatment-
experienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing Integrase …
experienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing Integrase …
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological …
D Armenia, V Spagnuolo, MC Bellocchi… - Journal of …, 2024 - academic.oup.com
Background To clarify whether next-generation sequencing (NGS) can be useful for
resistance assessment in virologically suppressed highly treatment-experienced (HTE) …
resistance assessment in virologically suppressed highly treatment-experienced (HTE) …
[HTML][HTML] Preclinical Profile of the HIV-1 maturation inhibitor VH3739937
B McAuliffe, P Falk, J Chen, Y Chen, SY Sit, J Swidorski… - Viruses, 2024 - mdpi.com
The HIV-1 maturation inhibitor (MI) VH3739937 (VH-937) inhibits cleavage between capsid
and spacer peptide 1 and exhibits an oral half-life in humans compatible with once-weekly …
and spacer peptide 1 and exhibits an oral half-life in humans compatible with once-weekly …
Trends of transmitted and acquired drug resistance in Europe from 1981 to 2019: a comparison between the populations of late presenters and non-late presenters
Background The increased use of antiretroviral therapy (ART) has decreased mortality and
morbidity of HIV-1 infected people but increasing levels of HIV drug resistance threatens the …
morbidity of HIV-1 infected people but increasing levels of HIV drug resistance threatens the …
Inflammation burden score in multidrug-resistant HIV-1 infection
T Clemente, R Caccia, L Galli, A Galli, A Poli… - Journal of Infection, 2023 - Elsevier
Objectives Four-class drug-resistant (4DR) people living with HIV (PLWH) are a fragile
population with a high burden of disease. No data on their inflammation and T-cell …
population with a high burden of disease. No data on their inflammation and T-cell …
[HTML][HTML] Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
Background We aimed at evaluating the temporal trend of drug-resistance and APOBEC
editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed …
editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed …
HIV-1 subtype diversity and factors affecting drug resistance among patients with virologic failure in antiretroviral therapy in Hainan province, China, 2014–2020
YU De E, YJ Xu, LI Mu, Y Yuan, HY Liang… - Biomedical and …, 2023 - Elsevier
Objective This study aimed to determine the HIV-1 subtype distribution and HIV drug
resistance (HIVDR) in patients with ART failure from 2014 to 2020 in Hainan, China …
resistance (HIVDR) in patients with ART failure from 2014 to 2020 in Hainan, China …